{"id":"https://openalex.org/W1985362631","doi":"https://doi.org/10.7448/ias.15.6.18337","title":"Absence of a pharmacokinetic interaction of rilpivirine with the P\u2010glycoprotein substrate digoxin in healthy volunteers","display_name":"Absence of a pharmacokinetic interaction of rilpivirine with the P\u2010glycoprotein substrate digoxin in healthy volunteers","publication_year":2012,"publication_date":"2012-11-01","ids":{"openalex":"https://openalex.org/W1985362631","doi":"https://doi.org/10.7448/ias.15.6.18337","mag":"1985362631"},"language":"en","primary_location":{"id":"doi:10.7448/ias.15.6.18337","doi":"https://doi.org/10.7448/ias.15.6.18337","is_oa":true,"landing_page_url":"https://doi.org/10.7448/ias.15.6.18337","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.7448/IAS.15.6.18337","source":{"id":"https://openalex.org/S66330005","display_name":"Journal of the International AIDS Society","issn_l":"1758-2652","issn":["1758-2652"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320728","host_organization_name":"International AIDS Society","host_organization_lineage":["https://openalex.org/P4310320728"],"host_organization_lineage_names":["International AIDS Society"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the International AIDS Society","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.7448/IAS.15.6.18337","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011202454","display_name":"Herta M. Crauwels","orcid":"https://orcid.org/0000-0002-4516-8830","observed_orcids":["https://orcid.org/0000-0002-4516-8830"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"H Crauwels","raw_affiliation_strings":["Janssen Infectious Diseases BVBA Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Infectious Diseases BVBA Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031100965","display_name":"Henri Deckx","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"H Deckx","raw_affiliation_strings":["Janssen Infectious Diseases BVBA Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Infectious Diseases BVBA Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051556802","display_name":"I Enweonye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"I Enweonye","raw_affiliation_strings":["Janssen Infectious Diseases BVBA Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Infectious Diseases BVBA Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018848186","display_name":"Marita Stevens","orcid":"https://orcid.org/0000-0001-5233-8917","observed_orcids":["https://orcid.org/0000-0001-5233-8917"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"M Stevens","raw_affiliation_strings":["Janssen Infectious Diseases BVBA Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Infectious Diseases BVBA Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030426323","display_name":"Richard M. W. Hoetelmans","orcid":"https://orcid.org/0000-0001-5582-3627","observed_orcids":["https://orcid.org/0000-0001-5582-3627"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"R Hoetelmans","raw_affiliation_strings":["Janssen Infectious Diseases BVBA Beerse Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Infectious Diseases BVBA Beerse Belgium","institution_ids":["https://openalex.org/I137982388"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I137982388"],"apc_list":{"value":2600,"currency":"USD","value_usd":2600},"apc_paid":{"value":2600,"currency":"USD","value_usd":2600},"fwci":0.4909,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.65866093,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"15","issue":"S4","first_page":"1","last_page":"2"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.8345000147819519,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.8345000147819519,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.09160000085830688,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.06120000034570694,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rilpivirine","display_name":"rilpivirine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/digoxin","display_name":"digoxin","score":0.9710000157356262},{"id":"https://openalex.org/keywords/p-glycoprotein","display_name":"P-glycoprotein","score":0.8809999823570251},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8489999771118164},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.824999988079071},{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.8980000019073486},{"id":"https://openalex.org/keywords/hiv","display_name":"HIV","score":0.6620000004768372},{"id":"https://openalex.org/keywords/steady-state-pharmacokinetics","display_name":"steady-state pharmacokinetics","score":0.7160000205039978},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.4000000059604645},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.6359999775886536},{"id":"https://openalex.org/keywords/urinary-excretion","display_name":"urinary excretion","score":0.4320000112056732},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.6589999794960022}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.9042685031890869},{"id":"https://openalex.org/C2777707475","wikidata":"https://www.wikidata.org/wiki/Q422222","display_name":"Digoxin","level":3,"score":0.8791525363922119},{"id":"https://openalex.org/C2778723075","wikidata":"https://www.wikidata.org/wiki/Q421547","display_name":"Rilpivirine","level":5,"score":0.8589339256286621},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7466356158256531},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6600700616836548},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.5634670853614807},{"id":"https://openalex.org/C2781432083","wikidata":"https://www.wikidata.org/wiki/Q422645","display_name":"Efavirenz","level":5,"score":0.5442105531692505},{"id":"https://openalex.org/C2779182219","wikidata":"https://www.wikidata.org/wiki/Q3765251","display_name":"Darunavir","level":5,"score":0.5438372492790222},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.490474671125412},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.46630823612213135},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.44341564178466797},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.3223320245742798},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32207438349723816},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.2324334979057312},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.22471219301223755},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.2096540331840515},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.1859024465084076},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.17176055908203125},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.7448/ias.15.6.18337","doi":"https://doi.org/10.7448/ias.15.6.18337","is_oa":true,"landing_page_url":"https://doi.org/10.7448/ias.15.6.18337","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.7448/IAS.15.6.18337","source":{"id":"https://openalex.org/S66330005","display_name":"Journal of the International AIDS Society","issn_l":"1758-2652","issn":["1758-2652"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320728","host_organization_name":"International AIDS Society","host_organization_lineage":["https://openalex.org/P4310320728"],"host_organization_lineage_names":["International AIDS Society"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the International AIDS Society","raw_type":"journal-article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.690.20","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.690.20","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://www.jiasociety.org/index.php/jias/article/viewFile/18337/1759/","raw_type":"text"}],"best_oa_location":{"id":"doi:10.7448/ias.15.6.18337","doi":"https://doi.org/10.7448/ias.15.6.18337","is_oa":true,"landing_page_url":"https://doi.org/10.7448/ias.15.6.18337","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.7448/IAS.15.6.18337","source":{"id":"https://openalex.org/S66330005","display_name":"Journal of the International AIDS Society","issn_l":"1758-2652","issn":["1758-2652"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320728","host_organization_name":"International AIDS Society","host_organization_lineage":["https://openalex.org/P4310320728"],"host_organization_lineage_names":["International AIDS Society"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the International AIDS Society","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1985362631.pdf","grobid_xml":"https://content.openalex.org/works/W1985362631.grobid-xml"},"referenced_works_count":2,"referenced_works":["https://openalex.org/W2099826019","https://openalex.org/W2142538462"],"related_works":["https://openalex.org/W7096057963","https://openalex.org/W2091555698","https://openalex.org/W2155524107","https://openalex.org/W7098525507","https://openalex.org/W4239283910","https://openalex.org/W2092025577","https://openalex.org/W2589525010","https://openalex.org/W2000428087","https://openalex.org/W4404471222","https://openalex.org/W2085167526"],"abstract_inverted_index":{"Rilpivirine":[0],"(RPV,":[1],"TMC278,":[2],"Edurant\u00ae)":[3],"is":[4,449],"a":[5,83,99,118,137],"next\u2010generation":[6],"non\u2010nucleoside":[7],"reverse":[8],"transcriptase":[9],"inhibitor":[10],"(NNRTI),":[11],"which":[12],"demonstrated":[13],"high":[14],"virologic":[15],"response":[16],"rates":[17],"and":[18,106,145,170,191,208,218,236,321,328,334,401,406],"non\u2010inferiority":[19],"versus":[20],"efavirenz":[21],"in":[22,27,46,90,96,107,125,143,154,162,223,233,375,391,395],"two":[23],"Phase":[24,84],"III":[25],"trials":[26,394],"HIV\u2010infected":[28],"patients":[29],"through":[30],"96":[31],"weeks":[32],"[":[33],"1":[34,225],",":[35],"2":[36],"].":[37],"RPV":[38,65,110,158,240,251,384,402,419,436,448],"has":[39],"been":[40],"shown":[41],"to":[42,389,414],"inhibit":[43],"P\u2010glycoprotein":[44],"(P\u2010gp)":[45],"vitro":[47],"with":[48,117,136,183],"an":[49],"apparent":[50],"IC50":[51],"of":[52,63,75,104,123,128,141,197,231,238,294,342,348,353,364,371,381,399,425,438,445],"9.2":[53],"\u00b5M":[54],"(3.4":[55],"\u00b5g/mL).":[56],"This":[57,81],"study":[58,132],"evaluated":[59],"the":[60,72,76,126,213,234,349,354,361,376,379,423,426,434,441],"in\u2010vivo":[61],"effect":[62],"steady\u2010state":[64,239,343,382],"25":[66,111,252],"mg":[67,102,112,121,244,249,253],"once":[68],"daily":[69],"(qd)":[70],"on":[71,166,203,314],"single\u2010dose":[73],"pharmacokinetics":[74,337,424],"probe":[77,427],"P\u2010gp":[78,428,446],"substrate":[79,429],"digoxin.":[80,430],"was":[82,373,403],"I,":[85],"open\u2010label,":[86],"randomised,":[87],"crossover":[88],"trial":[89],"22":[91,258],"HIV\u2010negative":[92],"volunteers.":[93,397],"Participants":[94],"received":[95],"one":[97],"session":[98,109],"single":[100,119],"0.5":[101,120,243,248],"dose":[103,122,228,437],"digoxin,":[105],"another":[108],"qd":[113,254],"for":[114,319,323,326,330],"16":[115],"days":[116],"digoxin":[124,142,232,242,247,295,336,372,400],"morning":[127],"Day":[129,167],"11.":[130,168],"All":[131],"drugs":[133],"were":[134,147,164,173,181,200,210,338,358,387,410],"taken":[135],"breakfast.":[138],"Pharmacokinetic":[139,179],"profiles":[140,161],"plasma":[144,163,333],"urine":[146,171,335],"determined":[148,165],"over":[149],"144":[150],"hours":[151],"after":[152],"dosing":[153],"each":[155],"session.":[156],"Steady\u2010state":[157],"24\u2010hour":[159],"pharmacokinetic":[160,205,216,229,296,316,356,385],"Plasma":[169],"samples":[172],"analysed":[174],"using":[175],"validated":[176],"LC\u2010MS/MS":[177],"methods.":[178,185],"parameters":[180,217,230,357,386],"calculated":[182,201,312],"non\u2010compartmental":[184],"The":[186,332,345,367],"least":[187],"square":[188],"(LS)":[189],"means":[190,291,351],"associated":[192],"90%":[193,346],"confidence":[194],"intervals":[195],"(CI)":[196],"treatment":[198],"ratios":[199,352],"based":[202,313],"log\u2010transformed":[204,315],"parameters.":[206,317],"Safety":[207],"tolerability":[209],"assessed":[211],"throughout":[212],"trial.":[214],"Digoxin":[215],"statistical":[219],"results":[220],"are":[221],"summarised":[222],"Table":[224],".":[226],"Single":[227],"absense":[235],"presence":[237,380],"Parameter":[241],"alone":[245],"(reference)":[246],"+":[250],"(test)":[255],"N":[256],"21":[257],"AUC4h":[259],"ng.h/mL":[260,264],"4.44\u00b11.21":[261],"4.46\u00b11.31":[262],"AUClast":[263,299],"26.6\u00b17.38":[265],"26.0\u00b17.86":[266],"Cmax,":[267],"ng/mL":[268],"1.93\u00b10.637":[269],"2.05\u00b10.678":[270],"tmax,":[271],"h":[272,278],"1.50":[273],"(0.68\u20133.00)":[274],"1.74":[275],"(0.65\u20133.02)":[276],"t\u00bd,":[277],"38.8\u00b16.30":[279],"38.3\u00b18.17":[280],"Durine":[281],"total,":[282],"%":[283],"47.7\u00b19.51":[284],"55.7\u00b112.2":[285],"CLR,":[286],"L/h":[287],"9.46\u00b12.54":[288],"11.2\u00b12.66":[289],"LS":[290,350],"(90%":[292],"CI)":[293],"parameter":[297],"ratios*":[298],"0.98":[300],"(0.93\u20131.04)a":[301],"Cmax":[302],"1.06":[303],"(0.97\u20131.17)a":[304],"CLR":[305],"1.16":[306],"(1.07\u20131.25)b":[307],"Ratios":[308],"presented":[309],"as":[310],"test/reference,":[311],"N=21":[318],"test":[320,327],"N=22":[322,329],"reference.":[324,331],"N=18":[325],"unaffected":[339],"by":[340,447],"co\u2010administration":[341],"RPV.":[344,383],"CIs":[347],"main":[355],"contained":[359],"within":[360],"0.80\u20101.25":[362],"boundaries":[363],"no":[365,411],"effect.":[366],"terminal":[368],"elimination":[369],"half\u2010life":[370],"similar":[374],"absence":[377],"or":[378],"comparable":[388],"those":[390],"previous":[392],"clinical":[393],"healthy":[396],"Administration":[398],"generally":[404],"safe":[405],"well":[407],"tolerated.":[408],"There":[409],"discontinuations":[412],"due":[413],"adverse":[415],"events.":[416],"In":[417,431],"conclusion,":[418],"does":[420],"not":[421,450],"affect":[422],"vivo,":[432],"at":[433],"recommended":[435],"25mg":[439],"qd,":[440],"observed":[442],"in\u2010vitro":[443],"inhibition":[444],"clinically":[451],"relevant.":[452]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}